Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Direct thrombin inhibitors: patents 2002-2012 (Review).

Kong Y, Chen H, Wang YQ, Meng L, Wei JF.

Mol Med Rep. 2014 May;9(5):1506-14. doi: 10.3892/mmr.2014.2025. Review.

PMID:
24604304
2.

Direct thrombin inhibitors.

Lee CJ, Ansell JE.

Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi: 10.1111/j.1365-2125.2011.03916.x. Review. Erratum in: Br J Clin Pharmacol. 2011 Oct;72(4):718. Dosage error in article text.

3.

Direct thrombin inhibitors in cardiovascular disease.

Arsenault KA, Hirsh J, Whitlock RP, Eikelboom JW.

Nat Rev Cardiol. 2012 May 1;9(7):402-14. doi: 10.1038/nrcardio.2012.61. Review.

PMID:
22547173
4.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
5.

Direct thrombin inhibitors for anticoagulation.

Nutescu EA, Wittkowsky AK.

Ann Pharmacother. 2004 Jan;38(1):99-109. Review.

PMID:
14742803
6.

Emerging anticoagulants: mechanism of action and future potential.

Klement P, Rak J.

Vnitr Lek. 2006 Mar;52 Suppl 1:119-22. Review.

PMID:
16637459
7.

Newer anticoagulants in cardiovascular disease: a systematic review of the literature.

Maan A, Padmanabhan R, Shaikh AY, Mansour M, Ruskin JN, Heist EK.

Cardiol Rev. 2012 Sep-Oct;20(5):209-21. doi: 10.1097/CRD.0b013e3182503e2d. Review.

PMID:
22370770
8.

Peptidomimetic thrombin inhibitors.

Kikelj D.

Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):487-91. Review.

PMID:
15692265
9.

Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases.

He LW, Dai WC, Li NG.

Molecules. 2015 Jun 15;20(6):11046-62. doi: 10.3390/molecules200611046. Review.

10.

New anticoagulant agents: direct thrombin inhibitors.

Nutescu EA, Shapiro NL, Chevalier A.

Clin Geriatr Med. 2006 Feb;22(1):33-56, viii. Review.

PMID:
16377466
11.

Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.

Leone G, Rossi E, Leone AM, De Stefano V.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):311-26. Review.

PMID:
15320782
12.

The pharmacology and therapeutic use of dabigatran etexilate.

Sarah S.

J Clin Pharmacol. 2013 Jan;53(1):1-13. doi: 10.1177/0091270011432169. Review.

PMID:
23400738
13.

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

Steffel J, L├╝scher TF.

J Cardiovasc Med (Hagerstown). 2009 Aug;10(8):616-23. doi: 10.2459/JCM.0b013e32832edac0. Review.

PMID:
19561526
14.

Ximelagatran: the first oral direct thrombin inhibitor.

Crowther MA, Weitz JI.

Expert Opin Investig Drugs. 2004 Apr;13(4):403-13. Review.

PMID:
15102589
15.

Complications in peripheral vascular interventions: emerging role of direct thrombin inhibitors.

Shammas NW.

J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):165-71. Review.

PMID:
15713917
16.

Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.

Eriksson BI, Dahl OE.

Drugs. 2004;64(6):577-95. Review. Erratum in: Drugs. 2004;64(8):912.

PMID:
15018589
17.

Use of direct thrombin inhibitors in acute coronary syndrome.

Nemergut C, Cheng JW.

Clin Ther. 2000 Aug;22(8):937-48; discussion 898.

PMID:
10972630
18.

Selective inhibition of coagulation factors: advances in antithrombotic therapy.

Bauer KA.

Semin Thromb Hemost. 2002 Jun;28 Suppl 2:15-24. Review.

PMID:
12073176
19.

The mechanism of action of thrombin inhibitors.

Bates SM, Weitz JI.

J Invasive Cardiol. 2000 Dec;12 Suppl F:27F-32. Review.

PMID:
11156731
20.

Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.

Winkler AM, Tormey CA; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists..

Am J Clin Pathol. 2013 Nov;140(5):610-22. doi: 10.1309/AJCP9VJS6KUKNCHW. Review.

Items per page

Supplemental Content

Support Center